who's who

3 Houston innovators to know this week

This week's Houston innovators to know includes Aleece Hobson of HX Venture Fund, Leland Putterman of Trivie, and Eleonore Cluzel of gBETA Houston. Photos courtesy

This week's roundup of who's who in Houston innovation include the HX Venture Fund's newest team member, a startup founder whose app is gamifying corporate training, and a Houston accelerator leader who's pivoted to digital.

Aleece Hobson, venture partner at the HX Venture Fund

Aleece Hobson joined the HX Venture Fund as venture partner. Photo courtesy of HXVF

The HX Venture Fund has expanded its portfolio of venture capital finds its invested in, and with that came a new team member for the fund of funds. Managing director Sandy Guitar — who runs the fund with Guillermo Borda — brought on Houston native Aleece Hobson as venture partner.

"Aleece joining is a phenomenal step for us — a dedicated resource and venture partner on activation," says Guitar on the hire. "I think it speaks to the seriousness of purpose we have to make this not just an investment platform, but one that moves the needle on Houston." Read more.

Leland Putterman, co-founder of Trivie Inc.

Trivie, which gamifies corporate training, has launched a new way for employees to connect with remote learning amid the pandemic. Photo via Trivie.com

Texas-based corporate training tool Trivie already had many clients with needs for safety training, COVID-19 has brought new compliance guidelines to the forefront of every industry. Currently, Trivie has made the CDC's coronavirus guidelines available to all of its clients for no additional charge to be used across their entire employment bases.

Additionally, with most of America's workforce working from home, Putterman expressed that it's common for employees to feel disconnected.

"The only way to maintain that company culture and close communication with confidence is to use something like Trivie," he says. "There's no feedback loop right now. The only way to bridge that gap is to have something like Trivie that's the glue." Read more.

Eléonore Cluzel, director of gBETA Houston

Eléonore Cluzel, director of gBETA Houston, joins the Houston Innovators Podcast to share how the cohort has been going — and to introduce each member of the inaugural cohort. Photo courtesy of gBETA

Things aren't going according to plan for Eléonor Cluzel, who is running the inaugural gBETA Houston cohort virtually. While it isn't ideal, Cluzel shares on the Houston Innovator's Podcast how she's adapted the program for digital — as well as introduces the five Houston companies in the program.

"Going virtual was a really good pivot on our end. I think that the cohort has adjusted very well," Cluzel says on the Houston Innovators Podcast. "It is tough. They put tremendous effort into it and I'm proud to be working with them." Read more.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News